Drug Trial Radar · NCT05679258
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
Last checked: Nov 19, 2026Latest source record: Jun 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
172
Actual
Start
Jan 31, 2023
Primary completion
Mar 16, 2024
Study completion Jun 28, 2024
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jan 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects
Conditions
- Multiple Myeloma
Interventions
HLX15Drug
A single dose (8 mg/kg) of HLX15 via intravenous infusion.
US-sourced DARZALEX®Drug
A single dose (8 mg/kg) of US-sourced DARZALEX® via intravenous infusion.
CN-sourced DARZALEX®Drug
A single dose (8 mg/kg) of CN-sourced DARZALEX® via intravenous infusion.
EU-sourced DARZALEX®Drug
A single dose (8 mg/kg) of EU-sourced DARZALEX® via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf).Time frame: Up to Day 91
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China
Sir Run Run Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.